Aktienbewertung
Konkurrenz
| Ticker | Preis | Prognose 1J | Prognose 2J | Börsenwert | Div Yld | Wachstumsrate |
|---|---|---|---|---|---|---|
|
NasdaqGS:AMGN
Amgen
|
319.04 | -14,06% | -5,45% | 171.144,12 | 2,89% | 5,31% |
|
NYSE:PFE
Pfizer
|
28.82 | 7,74% | 37,79% | 163.311,21 | 5,92% | -9,31% |
|
ENXTPA:SAN
Sanofi
|
90.56 | 17,5% | 36,18% | 113.210,59 | 4,1% | 8,19% |
|
NasdaqGS:REGN
Regeneron Pharmaceuticals
|
978.21 | -29,3% | -23,27% | 105.534,68 | 0% | 13,9% |
|
ASX:CSL
CSL
|
283.05 | 21,27% | 41,99% | 136.784,68 | 1,27% | 7,18% |
|
TSE:4568
Daiichi Sankyo Company
|
5486.00 | 0% | 0% | 10.516.360,76 | 1,11% | 0% |
|
NasdaqGS:MRNA
Moderna
|
129.06 | -.111,03% | -.107,61% | 49.460,92 | 0% | 0% |
|
TSE:4502
Takeda Pharmaceutical Company
|
4159.00 | 0% | 0% | 6.525.195,89 | 4,66% | 0% |
|
NasdaqGS:BIIB
Biogen
|
235.32 | -16,94% | -2,2% | 34.261,86 | 0% | -10,89% |
|
NasdaqGS:ALNY
Alnylam Pharmaceuticals Inc
|
147.40 | 0% | 0% | 18.644,89 | 0% | 0% |
|
NasdaqGS:BMRN
BioMarin Pharmaceutical
|
80.40 | 142,2% | 221,62% | 15.385,96 | 0% | 32,46% |
|
NasdaqGS:SRPT
Sarepta Therapeutics
|
132.50 | 0% | 0% | 12.505,49 | 0% | 0% |
|
NasdaqGS:INCY
Incyte
|
57.05 | 104,81% | 153,29% | 12.012,93 | 0% | 27,62% |
|
NasdaqGS:JAZZ
Jazz Pharmaceuticals
|
109.74 | 53,71% | 67,56% | 7.131,04 | 0% | 5,95% |
|
NasdaqGS:EXEL
Exelixis
|
21.12 | 39,15% | 69,39% | 6.338,53 | 0% | -8,84% |
|
NasdaqGM:NTLA
Intellia Therapeutics
|
26.22 | 0% | 0% | 2.359,79 | 0% | 0% |
|
NasdaqGS:DYN
Dyne Therapeutics
|
29.38 | 0% | 0% | 2.267,58 | 0% | 0% |
|
NasdaqGS:DCPH
Deciphera Pharmaceuticals
|
25.45 | 0% | 0% | 2.193,03 | 0% | 0% |
|
TSE:4516
Nippon Shinyaku
|
3730.00 | 0% | 0% | 261.328,78 | 3,2% | 0% |
|
NasdaqGS:BCRX
BioCryst Pharmaceuticals
|
6.36 | 0% | 0% | 1.087,36 | 0% | 0% |
